GlassScriptPhysician profile
Emma Grace Marcus
NPI 1689401820
$944.95
in general payments reported to CMS, 2019-2025
14 companies · $857 in 2025
The $857 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $88.32 · 2025: $857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $860 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $859.96 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $210.21 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $116.81 | 2025 | |
| Pfizer INC. | $115.27 | 2025 | |
| Progenics Pharmaceuticals, INC. | $106.05 | 2025 | |
| Sumitomo Pharma America, INC. | $82.04 | 2025 | Gemtesa |
| Accord Healthcare, INC. | $68.54 | 2024-2025 | |
| Immunitybio, INC. | $46.47 | 2025 | |
| Medtronic, INC. | $40.04 | 2024 | Interstim |
| Tolmar, INC. | $39.79 | 2025 | Eligard, Jatenzo |
| Abc Home Medical Supply, INC. | $30.76 | 2025 | |
| Ambu INC. | $26.14 | 2024 | |
| Ferring Pharmaceuticals INC. | $24.63 | 2025 | Adstiladrin |
| Merck Sharp & Dohme LLC | $21.36 | 2025 | Zerbaxa |
| Boston Scientific Corporation | $16.84 | 2025 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.